Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: KVUE )

24.09 +0.31 (+1.30%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about KVUE

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
How Is The Market Feeling About Kenvue?
Via Benzinga
In-Depth Technical Analysis of KENVUE INC.
With a solid technical rating of 8 out of 10, KENVUE INC (NYSE:KVUE) is showing strong indications of a possible breakout. 
Via Chartmill
FDA Wants To Pull Popular OTC Decongestant Used For Common Cold Over Effectiveness Concerns
FDA proposes removing oral phenylephrine from OTC drugs for nasal congestion, citing ineffectiveness. Public comments open before a final order is issued. 
Via Benzinga
Exposures Product Safety
Kenvue (KVUE) Q3 2024 Earnings Call Transcript
KVUE earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Listerine And Tylenol Maker Kenvue's Q3 Earnings: Revenue Miss On Weak Skin Health And Beauty Sales
Kenvue reports Q3 sales of $3.89 billion, slightly missing estimates. Strong growth in Essential Health offsets declines in Skin Health and Beauty. 
Via Benzinga
This Big New Development Could Be Bullish for Kenvue Stock
Can tinkering around the edges actually make this stock more attractive? 
Via The Motley Fool
Is Kenvue Stock a Buy Now?
The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved. 
Via The Motley Fool
10 Analysts Have This To Say About Kenvue
Via Benzinga
Navigating 10 Analyst Ratings For Kenvue
Via Benzinga
3 Dividend Stocks to Double Up on Right Now
While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio. 
Via The Motley Fool
Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock. 
Via The Motley Fool
Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
An activist investor is taking a stake in Kenvue stock. 
Via The Motley Fool
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
Nvidia Among Five Best S&P 500 Stocks Today
Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia was close behind. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
P/E Ratio Insights for Kenvue
Via Benzinga
There are signs that NYSE:KVUE may be ready to breakout.
KENVUE INC is setting up nicely for a breakout. 
Via Chartmill
Analyst Ratings For Kenvue
Via Benzinga
Dow Drops 320 Points as Stocks Cool Off
Stocks are stumbling out of the gate this week. 
Via Talk Markets
Topics Stocks
Exposures US Equities
What's Going On With Kenvue Stock Monday?
Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. 
Via Benzinga
Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?
U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the... 
Via Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Elf Beauty appeared to rally along with KVUE on Monday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge. 
Via Talk Markets
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc, the company behind popular consumer products like Tylenol and Listerine. 
Via Benzinga
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations. 
Via The Motley Fool
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
Via Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win. 
Via Benzinga
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
Via The Motley Fool
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets. 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.